NCT04397393

Brief Summary

The primary aim is to verify if camel milk consumption has an impact on the amount of Midazolam needed to achieve a satisfactory level of sedation for oocyte retrieval, compared to patients never having consumed camel milk.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 17, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 21, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2020

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 10, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2020

Completed
Last Updated

December 11, 2020

Status Verified

December 1, 2020

Enrollment Period

1 month

First QC Date

May 17, 2020

Last Update Submit

December 10, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform the OPU

    Mean dosage of Midazolam for both groups (Camel milk consumption vs no camel milk consumption

    1 day

Study Arms (2)

non-camel milk consumption

non-camel milk consumption over life time

Drug: Midazolam

camel milk consumption

camel milk consumption at least once during lifetime, with 2 subgroups of camel milk consumption: once, twice, three times; as well as regularly (daily, once per week, once per month, once per year).

Drug: Midazolam

Interventions

Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU

camel milk consumptionnon-camel milk consumption

Eligibility Criteria

Age18 Years - 48 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

population is defined by all females of Arab origin, booked for oocyte retrieval for the first time in our center

You may qualify if:

  • Arab origin
  • Female 18 -48 years of age
  • BMI \< 37 kg/m2
  • All ovarian stimulation protocols

You may not qualify if:

  • Previous oocyte retrieval at our center
  • Post chemo therapy
  • Illicit drug use
  • Chronic pain medication
  • Medication which is known to increase the activity of liver enzymes
  • Any alcohol consumption
  • Previous vaginal delivery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IVI Middle East Fertility Clinic

Abu Dhabi, 60202, United Arab Emirates

Location

Related Links

MeSH Terms

Interventions

Midazolam

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Nils Engelmann, MD

    IVI Middle East Fertility Clinic LLC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Anesthesia Consultant

Study Record Dates

First Submitted

May 17, 2020

First Posted

May 21, 2020

Study Start

July 1, 2020

Primary Completion

August 10, 2020

Study Completion

August 10, 2020

Last Updated

December 11, 2020

Record last verified: 2020-12

Locations